ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that it will be hosting a Virtual Investor Day event on Tuesday, February 13, 2024, starting at 3:00 p.m. ET.
The virtual-only webcast event will feature presentations from select members of the management team. The event will provide an overview of Zomedica's portfolio of innovative products, world-class manufacturing facilities, recent business developments, and scientific and information technology capabilities. In addition, key drivers of future growth and commercial execution along with the broader animal health addressable market opportunity and financial position will be discussed.
A live question-and-answer session will follow management's webcast presentation.
Event: Zomedica Virtual Investor Day 2024
Date: Tuesday, February 13, 2024
Time: 3:00 p.m. Eastern Time
Webcast: Zomedica Virtual Investor Day
Full replay of the webcast will be available on Zomedica's website at Events & Presentations | Zomedica Inc.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit zomedica.com.
Follow Zomedica
Investor Contact:
Zomedica Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-734-369-2555
| Last Trade: | US$0.12 |
| Daily Volume: | 12,083,028 |
| Market Cap: | US$117.590M |
November 27, 2024 November 14, 2024 November 08, 2024 November 07, 2024 October 24, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
